Insight

Sep 11, 2024, 07:24

A roadmap for designing better immunotherapies – Cancer Research Institute

Cancer Research Institute (CRI) made the following post on LinkedIn:

“New findings from researchers, including 2022 William B. Coley Award recipient Dr. Judy Lieberman of Boston Children’s Hospital, indicate that tumors edit multiple genes to avoid recognition by the immune system. Published in Springer Nature Group’s Nature Immunology, the study additionally demonstrates a way to override these edits, by curbing tumor growth in a human-like mouse model of breast cancer, ‘which is notoriously resistant to immunotherapy.’ Discover how this study could provide a roadmap for designing better immunotherapies.”

Read further.
Source: Cancer Research Institute (CRI)/LinkedIn

Boston Children’s Hospital Breast Cancer cancer Cancer research Cancer Research Institute CRI Gene Editing immune system immunotherapy Judy Lieberman Nature Immunology OncoDaily Oncology Springer Nature Group

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage